Spinosad - ParaPRO

Drug Profile

Spinosad - ParaPRO

Alternative Names: LY-232105; Natroba; NatrOVA creme rinse 1%; PP-105; XDE-105

Latest Information Update: 29 Dec 2015

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer ParaPRO
  • Class Antiparasitics; Macrolides
  • Mechanism of Action Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pediculosis
  • Suspended Scabies

Most Recent Events

  • 17 Dec 2015 Suspended - Phase-III for Scabies (In adolescents, In children, In adults) in USA (Topical)
  • 17 Dec 2015 ParaPRO suspends recruitment in a phase III trial for Scabies in USA (Topical) (NCT02485704)
  • 02 Jul 2015 ParaPRO completes enrolment in a phase III trial for Scabies in USA (Topical) (NCT02485717)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top